EMQN and GenQA are proud to announce the release of a new pilot EQA scheme for prostate cancer testing using cfDNA in plasma. The scheme is applicable to labs testing HRR pathway genes (BRCA1 and BRCA2 testing will be mandatory).
There is no cost to participate in this pilot EQA scheme but participation is limited to the first 50 laboratories that sign up via the EMQN or GenQA websites.
To find out more, please click on the image below:
EMQN and GenQA would like to gratefully acknowledge the educational grant from Merck Sharpe and Dome (MSD) and Astrazeneca that has made it possible to deliver this new EQA scheme to our members